Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease management programs

E P Armstrong1, P C Langley

  • 1College of Pharmacy, Center for Pharmaceutical Economics, University of Arizona, Tucson 85721, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of adjustable gastric banding on quality of life and weight loss in the Helping Evaluate Reduction in Obesity (HERO) registry study: 2 year analysis.

Current medical research and opinion·2015
Same author

The prevalence, correlates and treatment of pain in the European Union.

Current medical research and opinion·2011
Same author

Economic burden of asthma: implications for outcomes and cost-effectiveness analyses.

Expert review of pharmacoeconomics & outcomes research·2009
Same author

Criteria for the economic evaluation of lipid studies in health systems.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

Commentary on Langley and McKenney Papers.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forum.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Sonrotoclax.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Disease management (DM) programs systematically evaluate treatments to optimize patient outcomes and reduce healthcare costs. These programs involve partnerships, data analysis, and risk-sharing for effective health system management.

Area of Science:

  • Health Services Research
  • Pharmaceutical Management
  • Healthcare Economics

Background:

  • Managed care organizations (MCOs) implement disease management (DM) to control costs and improve patient care.
  • DM programs systematically assess treatment options, resource utilization, and patient outcomes.
  • Partnerships between MCOs and pharmaceutical companies are common in DM arrangements.

Purpose of the Study:

  • To describe disease management activities within managed care.
  • To discuss the implementation and monitoring of DM programs.
  • To highlight the role of data and risk-sharing in DM contracts.

Main Methods:

  • Systematic evaluation of treatment options, resource use, and patient outcomes.
  • Development of DM arrangements with defined patient groups and target outcomes.

Related Experiment Videos

  • Data collection, monitoring, and reporting based on contractual agreements.
  • Risk-sharing models and capitated case management.

    • Main Results:

    • DM programs facilitate the provision of standardized healthcare at the lowest possible cost.
    • Interventions focus on modifying prescribing patterns and patient compliance.
    • Contracts specify treatment guidelines, data requirements, and outcome assessments.
    • Risk-sharing encourages a focus on optimal drug use within total treatment costs.

    Conclusions:

    • Disease management contracts require a holistic view of treatment impact on the health system.
    • The primary goal is to reduce overall treatment costs while achieving desired patient outcomes.
    • DM necessitates a shift from market share focus to optimizing drug utilization and system costs.